1. Montori VM, Devereaux PH, Adhikari NKJ, et al. Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:2203–2209. [PubMed] 2. Mueller PS, Montori VM, Bassler D, et al. Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med. 2007;146:878–881. [PubMed] 3. Bassler D, Montori VM, Briel M, et al. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61:241–246. [PubMed] 4. Wilcox RA, Djulbegovic B, Guyatt GH, et al. Randomized trials in oncology stopped early for benefit. J Clin Oncol. 2008;26:18–19. [PubMed] 5. Trotta F, Apolone G, Garattini S, et al. Stopping a trial early in oncology: For patients or for industry? Ann Oncol. 2008;19:1347–1353. [PubMed] 6. Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients. J Clin Oncol. 2008;16:2787–2788. [PubMed] 7. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. [PubMed] 8. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med. 1995;122:321–326. [PubMed] 9. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598. [PubMed] 10. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–1627. [PubMed]
11. Lauer SJ, Toledano S, Winick N, et al. A comparison of early intensive methotrexate/mercaptopurine (MTX/MP) vs early intensive alternating chemotherapy for high-risk acute lymphoblastic leukemia (HR-ALL): A Pediatric Oncology Group (POG) randomized phase III study. Proc Am Soc Clin Oncol. 1995;14:342. abstr A1030.
12. Lauer SJ, Shuster JJ, Mahoney DH, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial. Leukemia. 2001;15:1038–1045. [PubMed]
13. Fetting J, Gray R, Abeloff M, et al. CAF vs a 16-week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An intergroup study. Proc Am Soc Clin Oncol. 1995;14:96. abstr A83.
14. Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. J Clin Oncol. 1998;16:2382–2391. [PubMed]
15. Rai KR, Peterson B, Kolitz J, et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL): A randomized inter-group study. Blood. 1995;86:A607. abstr 2414.
16. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757. [PubMed]
17. Al-Sarraf M, LeBlanc M, Giri PG, et al. Superiority of chemoradiotherapy (CT-RT) vs. radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc Am Soc Clin Oncol. 1996;15:313a. abstr A882.
18. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317. [PubMed]
19. Al-Sarraf M, Le Blanc M, Giri P, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nasopharyngeal cancer (NPC): Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study—Final report. Proc Am Soc Clin Oncol. 2001;20:227a. abstr A905.
20. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–1028. [PubMed] 21. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671. [PubMed]
22. Albain K, Green S, Osborne K, et al. Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol. 1997;16:128a. abstr A450.
23. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat. 2005;90:195. abstr A37.
24. Peters WA, Liu PY, Barrett R, et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. Gynecol Oncol. 1999;72:443. abstr A1. [PubMed] 25. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613. [PubMed]
26. Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer. Proc Am Soc Clin Oncol. 1998;17:101a. abstr 390.
27. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983. [PubMed]
28. George SI, Green MR. Controversies in the early reporting of a clinical trial in early breast cancer. In: DeMets DL, Furberg CD, Friedman LM, editors. Data Monitoring in Clinical Trials. New York, NY: Springer; 2006. pp. 346–359.
29. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143. [PubMed] 30. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872–880. [PubMed] 31. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771. [PubMed] 32. Press OW, LeBlanc M, Lichter A, et al. A phase III randomized intergroup trial of subtotal lymphoid irradiation (STLI) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). Blood. 2000;96:575a. abstr A2471. [PubMed] 33. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19:4238–4244. [PubMed] 34. Roach M, III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911. [PubMed] 35. Lawton CA, DeSilvio M, Roach M, 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–655. [PMC free article] [PubMed]
36. Roach M, III, Lu JD, Lawton C, et al. A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 9413. Int J Radiat Oncol Biol Phys. 2001;51(suppl):3. abstr plenary 5.
37. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460–2465. [PubMed]
38. Markman M, Liu P, Wilczynski S, et al. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. J Clin Oncol. 2006;24(suppl):257s. abstr 5005.
39. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC)—Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol. 2002;21:128a. abstr 511.
40. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30. [PubMed] 41. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802. [PubMed] 42. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005;97:1262–1271. [PubMed]
43. Hochster HS, Weller E, Ryan T, et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol. 2004;22(suppl 14):558s. abstr 6502.
44. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106:106a. abstr 349.
45. Rajkumar SV, Blood E, Vesole DH, et al. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(suppl):560s. abstr 6508.
46. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436. [PubMed]
47. Seibel NL, Steinherz PG, Sather HN, et al. Early treatment intensification improves outcome in children and adolescents with acute lymphoblastic leukemia (ALL) presenting with unfavorable features who show a rapid early response (RER) to induction chemotherapy: A report of CCG1961. Blood. 2003;102:224A–225A. abstr 787.
48. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood. 2008;111:2548–2555. [PubMed] 49. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23(suppl):1s. abstr 2. [PubMed]
50. Giantonio BJ. ECOG-E3200: FOLFOX4 with bevacizumab versus FOLFOX4 versus bevacizumab in patients with previously treated advanced colorectal cancer. Colorectal Cancer Update. 2005;4:18–21.
51. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544. [PubMed]
52. Flinn IW, Kumm E, Grever MR, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup trial E2997. Blood. 2004;104:139a. abstr 475.
53. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793–798. [PubMed] 54. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684. [PubMed]
55. Perez E, Romond E, Suman V, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(suppl):6s. abstr 512.
56. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. [PubMed]
57. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94(suppl 1):S6. abstr 3.
58. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676. [PubMed]
59. Burnell MJ, Levine MN, Chapman JA, et al. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA. 21). J Clin Oncol. 2007;25(suppl):15s. abstr 550.
60. Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA. 21: Results of an interim analysis.. 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. abstr A53.
61. Cannistra SA. The ethics of early stopping rules: Who is protecting whom? J Clin Oncol. 2005;22:1542–1545. [PubMed] 62. Pater J, Goss P, Ingel J, et al. The ethics of early stopping rules. J Clin Oncol. 2005;23:2862–2863. [PubMed]
63. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol. 2007;25(suppl):240s. abstr 5023.
64. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer. 1976;34:535–612. [PMC free article] [PubMed] 65. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556. [PubMed] 66. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials. 1989;10:209S–221S. [PubMed] 67. Fan X, DeMets DL, Lan KKG. Conditional bias of point estimates following a group sequential test. J Biopharm Stat. 2004;14:505–530. [PubMed] 68. Goodman SN. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146:882–887. [PubMed] 69. Freidlin B, Korn EL. Stopping clinical trials early for benefit: Implact on estimation. Clin Trials. in press. [PubMed] 70. Wheatley K, Clayton D. Be skeptical about unexpected large apparent treatment effects: The case of an MRC AML12 randomization. Control Clin Trials. 2003;24:66–70. [PubMed] 71. Korn EL, Freidlin B, George SL. Data monitoring and large apparent treatment effects. Control Clin Trials. 2004;25:67–69. [PubMed]
72. Clayton D, Wheatley K. Reply to the letter of Korn, et al. Control Clin Trials. 2004;25:71–72.
73. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc A. 1994;157:357–387.
74. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvanct paclitaxel plus carboplatin compared with observation in stage 1B non–small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;31:5043–5051. [PMC free article] [PubMed]
75. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non–small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2004;22(suppl):621s. abstr 7019.